Improve Drug Discovery Screening with the MaxCyte STX Scalable Transfection System
Product News: Improve Drug Discovery Screening with the MaxCyte STX Scalable Transfection System
04 Feb 2011
The MaxCyte® STX™ Scalable Transfection System enables rapid, reproducible production of transfected cells for expressing Ion Channels, GPCRs, and other targets of interest for Protein Production, HTS, and other Cell-Based Assays. The unique scalability (transfect 1010 cells in <30 minutes) and flexibility of the MaxCyte STX eliminate the need for stable cell lines and help you develop assays faster, in biologically relevant cell types.
The MaxCyte STX uses a patented flow electroporation technology to transiently transfect a variety of cell types, including historically difficult-to-transfect cells such as primary cells, with a range of biomolecules including DNA, RNA, siRNA, proteins or other molecules of interest. This single system has the scalability to transfect as few as 5 x 105 cells within seconds for assay development or as many as 1 x 1010 cells for large scale screening and protein production. If more suitable to assay scheduling, transfected cells can also be aliquoted and cryopreserved for future use. The unmatched flexibility, performance and ease of use of the MaxCyte STX translate into shorter times to screen, greater laboratory productivity,and higher quality assays with greater physiological relevance.